Patient-derived tumor-like cell clusters for drug testing enable therapeutic response of metastatic gastric cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500095824

Enrollment

Unknown

Registered

2025-01-14

Start date

2023-11-14

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic gastric cancer

Interventions

experimental group:Patient-derived tumor-like cell clusters for drug testing in metastatic gastric cancer

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age 18~75 years at registration; 2.Histologically or cytological confirmed gastric carcinoma; 3.Recurrence and metastasis after radical resection; tumor recurrence after first-line or second-line therapy; 4.Patients needed operation or abdominal drainage; 5.Gastric cancer patients requiring therapy; 6.Eastern Cooperative Oncology Group (ECOG) score = 2; 7.Written (signed) informed consent;

Exclusion criteria

Exclusion criteria: 1.Tumor sample was unavailable; 2.During pregnancy, within 28 days of post parturition, or during lactation; 3.Patients with poor compliance; 4.Clinically severe (i.e. active) heart disease or cerebrovascular disease; 5.Synchronous or metachronous malignancies; 6.Severe mental disease, uncontrolled epilepsy, or central nervous system disease; 7.Patients were not taken into consideration by investigator;

Design outcomes

Primary

Measure	Time frame
progression-free survival (PFS);	—

Secondary

Measure	Time frame
objective response rate;overall survival (OS);	—

Countries

China

Contacts

Public ContactLiu Wentao

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

lwt11484@rjh.com.cn+86 21 6437 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026